| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.15 | 0.3 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.15 | 0.3 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.052 | 0.3 |